Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) on March 19, 2020. The report details the entry into a material definitive agreement regarding the company's credit facility and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Debt Structure
- Debt Facility: The company entered into the Seventh Amendment to its Credit Agreement with JPMorgan Chase Bank, N.A., BMO Harris Bank, N.A., and City National Bank.
- Leverage Ratio: The maximum Total Leverage Ratio was retroactively increased to 5.75:1.0 for the fiscal quarter ended February 23, 2020. As of that date, the actual ratio was 5.55:1.0. The ratio is scheduled to decrease to 5.00:1.0 for the quarter ending May 31, 2020.
- EBITDA Adjustments: Definitions of EBITDA and Unadjusted EBITDA were modified to include specific charges related to Tanok legal expenses and escrow receivable reserves.
- Transaction Costs: The company paid $482,000 in bank fees, including a $110,000 arrangement fee, a $321,000 amendment fee, and $51,000 in related expenses.
- Interest Rates: Interest is based on the Total Leverage Ratio, ranging from Prime + 0.25% to 3.00% or Eurodollar + 1.25% to 4.00%, plus applicable commitment fees.
Material Changes and Covenants
The Seventh Amendment introduces significant new financial covenants and restrictions effective immediately:
- Minimum EBITDA Thresholds: The company must meet cumulative minimum Unadjusted EBITDA thresholds of $2,745,000 by March 22, 2020; $6,186,000 by April 19, 2020; and $20,000,000 by May 31, 2020.
- Capital Expenditure Limitation: Capital expenditures are restricted to an aggregate of $37,427,000 for the four fiscal quarters ending May 31, 2020.
- Reporting Requirements: The company must provide monthly financial statements and certifications to lenders.
- Acceleration Clause: Failure to comply with the Fixed Charge Coverage Ratio, Total Leverage Ratio, Minimum EBITDA Threshold, or Capital Expenditure Limitation by the end of March 2020, April 2020, or May 2020 will accelerate the Term Maturity Date from October 25, 2022, to September 23, 2021.
Management Commentary and Personnel Changes
- Executive Appointment: Brian McLaughlin was appointed as Chief Financial Officer and Vice President of Finance and Administration, transitioning from his role as interim CFO (held since January 8, 2020). He previously served as CFO for Curation Foods and Organicgirl.
- Outlook: The filing does not provide specific revenue guidance or forward-looking financial projections beyond the covenant thresholds required to avoid loan acceleration.
Investor Verification Checklist
- Verify the company's ability to meet the strict Minimum EBITDA Thresholds ($2.7M, $6.2M, and $20M) by the upcoming deadlines to prevent debt acceleration.
- Confirm the current status of Capital Expenditures to ensure they remain within the $37.4M limit for the specified period.
- Review the impact of the Tanok legal expenses and escrow reserves on the adjusted EBITDA calculations.
- Monitor the Total Leverage Ratio to ensure it remains below the 5.75:1.0 cap for the current quarter and adheres to the scheduled reduction thereafter.
- Assess the liquidity implications of the $482,000 immediate fee payment and ongoing interest rate spreads.